Suppr超能文献

描述社区中使用阿片类药物的人群的阿片类药物戒断体验和后果。

Characterizing Opioid Withdrawal Experiences and Consequences Among a Community Sample of People Who Use Opioids.

机构信息

Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, La Jolla, California, USA.

Department of Population and Public Health Sciences, Keck School of Medicine of University of Southern California, Los Angeles, California, USA.

出版信息

Subst Use Misuse. 2024;59(6):886-894. doi: 10.1080/10826084.2024.2306221. Epub 2024 Jan 29.

Abstract

BACKGROUND

Opioid withdrawal symptoms are a highly salient and consequential health condition experienced by people who use opioids (PWUO). This study utilized qualitative interviews to explore opioid withdrawal experiences and consequences among PWUO in Los Angeles County, USA.

METHODS

Semi-structured qualitative interviews were conducted with 22 PWUO (aged 27-63 years) between May 2021 and May 2022. Participants self-reported opioid and injection drug use in the last 30 days. We employed an inductive thematic approach to systematically code and synthesize textual interview data.

RESULTS

Participants experienced withdrawal symptoms frequently, with many going to great lengths to avoid them. Withdrawal pain was described as incapacitating and interfered with PWUO's ability to sustain regular employment and ensure stable housing. Avoiding withdrawal was described as influential in driving decisions to continue using opioids. Mechanisms for managing withdrawal included using other substances to the point of sedation. PWUO who transitioned from heroin to fentanyl use revealed more frequent, painful, and faster onset of withdrawal symptoms. Adverse withdrawal experiences and fear of precipitated withdrawal from buprenorphine were barriers to treatment initiation and continuation.

CONCLUSION

Withdrawal symptoms among PWUO increase health risk. Improved strategies to treat opioid withdrawal are urgently needed. Solutions such as safe supply and intentional opioid withdrawal interventions (educational trainings, withdrawal comfort kits) are needed to improve withdrawal management and reduce opioid-related harm.

摘要

背景

阿片类药物戒断症状是使用阿片类药物的人(PWUO)经历的一种高度显著和后果严重的健康状况。本研究利用定性访谈,探讨了美国洛杉矶县 PWUO 中的阿片类药物戒断体验和后果。

方法

2021 年 5 月至 2022 年 5 月期间,对 22 名 PWUO(年龄 27-63 岁)进行了半结构式定性访谈。参与者自我报告了过去 30 天内的阿片类药物和注射药物使用情况。我们采用了一种归纳主题的方法,对文本访谈数据进行了系统的编码和综合。

结果

参与者经常经历戒断症状,许多人竭尽全力避免戒断症状。戒断疼痛被描述为使人丧失能力,干扰 PWUO 维持正常就业和确保稳定住房的能力。避免戒断被描述为影响继续使用阿片类药物的决策的因素。管理戒断的机制包括使用其他物质至镇静状态。从海洛因过渡到芬太尼使用的 PWUO 报告称,戒断症状更频繁、更痛苦、更快发作。戒断的不良反应和对丁丙诺啡引发戒断的恐惧是开始和继续治疗的障碍。

结论

PWUO 中的戒断症状增加了健康风险。迫切需要改进治疗阿片类药物戒断的策略。需要安全供应和有意的阿片类药物戒断干预措施(教育培训、戒断舒适包)等解决方案,以改善戒断管理并减少阿片类相关伤害。

相似文献

1
Characterizing Opioid Withdrawal Experiences and Consequences Among a Community Sample of People Who Use Opioids.
Subst Use Misuse. 2024;59(6):886-894. doi: 10.1080/10826084.2024.2306221. Epub 2024 Jan 29.
4
"Anything can happen": experiences of people using opioids in a xylazine market.
Harm Reduct J. 2025 Jul 31;22(1):134. doi: 10.1186/s12954-025-01275-z.
6
Buprenorphine for the management of opioid withdrawal.
Cochrane Database Syst Rev. 2000(3):CD002025. doi: 10.1002/14651858.CD002025.
7
Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.
JAMA Netw Open. 2024 Jul 1;7(7):e2420702. doi: 10.1001/jamanetworkopen.2024.20702.
8
Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl.
JAMA Netw Open. 2024 Sep 3;7(9):e2435895. doi: 10.1001/jamanetworkopen.2024.35895.
9
Opioids for cancer pain - an overview of Cochrane reviews.
Cochrane Database Syst Rev. 2017 Jul 6;7(7):CD012592. doi: 10.1002/14651858.CD012592.pub2.

引用本文的文献

2
"You take care of people, people will take care of you": Moral Economies and an Unpredictable Drug Market.
PLoS One. 2025 Apr 2;20(4):e0320423. doi: 10.1371/journal.pone.0320423. eCollection 2025.
3
Law Enforcement Drug Seizures and Opioid-Involved Overdose Mortality.
JAMA Netw Open. 2025 Mar 3;8(3):e251158. doi: 10.1001/jamanetworkopen.2025.1158.
4
Fentanyl, Heroin, Methamphetamine, and Cocaine Analyte Concentrations in Urine Drug Testing Specimens.
JAMA Netw Open. 2024 Oct 1;7(10):e2441063. doi: 10.1001/jamanetworkopen.2024.41063.
5
Correlates of fentanyl preference among people who use drugs in Rhode Island.
Harm Reduct J. 2024 Sep 14;21(1):169. doi: 10.1186/s12954-024-01089-5.
6
A qualitative evaluation of a fentanyl patch safer supply program in Vancouver, Canada.
Int J Drug Policy. 2024 Sep;131:104547. doi: 10.1016/j.drugpo.2024.104547. Epub 2024 Aug 17.

本文引用的文献

1
Experiences with Medications for Addiction Treatment Among Emergency Department Patients with Opioid Use Disorder.
West J Emerg Med. 2023 Feb 22;24(2):236-242. doi: 10.5811/westjem.2022.9.57821.
3
Rapid changes in illegally manufactured fentanyl products and prices in the United States.
Addiction. 2022 Oct;117(10):2745-2749. doi: 10.1111/add.15942. Epub 2022 Jun 8.
4
The introduction of fentanyl on the US-Mexico border: An ethnographic account triangulated with drug checking data from Tijuana.
Int J Drug Policy. 2022 Jun;104:103678. doi: 10.1016/j.drugpo.2022.103678. Epub 2022 Apr 11.
6
Developing A Rapid Transfer from Opioid Full Agonist to Buprenorphine: "Ultrarapid Micro-Dosing" Proof of Concept.
J Psychoactive Drugs. 2023 Jan-Mar;55(1):94-101. doi: 10.1080/02791072.2022.2039814. Epub 2022 Feb 13.
7
Transition from injecting opioids to smoking fentanyl in San Francisco, California.
Drug Alcohol Depend. 2021 Oct 1;227:109003. doi: 10.1016/j.drugalcdep.2021.109003. Epub 2021 Aug 27.
8
Purposeful Fentanyl Use and Associated Factors among Opioid-Dependent People Who Inject Drugs.
Subst Use Misuse. 2021;56(7):979-987. doi: 10.1080/10826084.2021.1901931. Epub 2021 Mar 26.
10
The opioid crisis and HIV in the USA: deadly synergies.
Lancet. 2021 Mar 20;397(10279):1139-1150. doi: 10.1016/S0140-6736(21)00391-3. Epub 2021 Feb 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验